Citigroup Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $68
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz has initiated coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating and set a price target of $68.

March 06, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has initiated coverage on Crinetics Pharmaceuticals with a Buy rating and a price target of $68.
The initiation of coverage by a major financial institution like Citigroup, especially with a Buy rating and a significant price target of $68, is likely to generate positive sentiment among investors. This could lead to increased buying activity in the short term, pushing the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100